Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2015
At a glance
- Drugs Bortezomib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Sep 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 06 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 13 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History